List view / Grid view
An oral small molecule CGRP antagonist has been recommended for episodic migraines in National Institute for Health and Care Excellence (NICE) final draft guidance.
Initial data from study results being presented at the 75th American Academy of Neurology Annual Meeting indicate that an oral CGRP inhibitor reduced episodic migraine frequency.
Amgen announces positive results from the first and only randomised, double-blind, head-to-head study comparing Aimovig® to topiramate.
A 12-week study revealed that atogepant reduced migraines and headaches and resulted in a 50 percent reduction in mean monthly migraine days.
The UK's NICE has recommended Emgality (galcanezumab) for the prevention of migraine in adults with episodic and chronic migraine.